Abstract
Circulating proteins influence disease risk and are valuable drug targets. To enhance the discovery of protein-phenotype associations and identify potential therapeutic targets across diverse populations, we conducted proteome-phenome-wide Mendelian randomization in three ancestries, followed by comprehensive sensitivity analyses. We tested the potential causal effects of up to 2,265 unique proteins on a curated list of 355 distinct phenotypes, identifying 726,035 protein-phenotype pairs in European, 33,078 in African, and 115,352 in East Asian ancestries. Notably, 119 proteins were instrumentable only in African ancestry and 17 proteins only in East Asian ancestry due to allele frequency differences that are common in these ancestries but rare in European ancestry. We identified 3,949, 56, and 325 unique protein-phenotype pairs in European, African, and East Asian ancestries, respectively, and assessed their druggability using multiple databases. We highlighted the causal role of IL1RL1 in inflammatory bowel diseases, supported by multiple orthogonal lines of evidence. Taken together, this study underscores the importance of multi-ancestry inclusion and offers a comprehensive atlas of protein-phenotype associations across three ancestries, enhancing our understanding of proteins involved in disease etiology and potential therapeutic targets. Results are available at the Common Metabolic Diseases Knowledge Portal (https://broad.io/protein_mr_atlas).
Competing Interest Statement
Y.C. is an employee, J.B.R. is the CEO, and W.Z., G.B.-L., and T.L. have been consulting for 5 Prime Sciences. However, this study was performed separately with no relationship to 5 Prime Sciences. J.B.R.'s institution has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline and Biogen for projects unrelated to this research. The other authors declare no conflict of interest.
Funding Statement
This research has been conducted using the UK Biobank Resource under Application Number 27449. C.-Y.S. is supported by a CIHR Canada Graduate Scholarship Doctoral Award (Funding Reference Number: 187673), an FRQS doctoral training scholarship, and a Lady Davis Institute/TD-Bank Scholarship. T.L. has been supported by start-up funding from the Office of the Vice Chancellor for Research and Graduate Education, School of Medicine and Public Health, and Department of Population Health Sciences at the University of Wisconsin-Madison. S.Y. is supported by the Japan Society for the Promotion of Science. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. We acknowledge Servier Medical Art (https://smart.servier.com/) for providing images that were used to create diagrams in this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All contributing cohorts obtained ethical approval from their institutional ethics review boards. The contributing proteomics cohorts include the Atherosclerosis Risk in Communities (ARIC) Study, deCODE study, Fenland study, UK Biobank, and Kyoto University Nagahama study. The UK Biobank has approval from the North West Multi-centre Research Ethics Committee as a Research Tissue Bank.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
